Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
29 August 2024 | Story Anthony Mthembu | Photo Harmse Photography
Ross van Reenen
Ross van Reenen, CEO of the Toyota Free State Cheetahs.

The Business School at the University of the Free State (UFS) recently hosted the CEO of the Toyota Free State Cheetahs, Ross van Reenen, for a guest lecture. Van Reenen presented the guest lecture in the Business School Auditorium on the UFS Bloemfontein Campus on 21 August 2024.

Reflecting on Van Reenen’s address

In a lecture addressed to an auditorium filled with UFS staff and students, Van Reenen’s talk was divided into several sections. Firstly, he spoke about the concept of the ‘black swan’ in reference to the book written by Nassim Nicholas Taleb, titled The Black Swan: The Impact of the Highly Improbable. Referring to Taleb’s book, Van Reenen defined a ‘black swan’ as a rare event that has a severe impact, and the occurrence of which people try to explain. He used some examples to explore this concept as well as its implications, including COVID-19 and its impact on the world, and the tragic death of the people in the Titanic disaster. However, he delved deeper into 9/11 and the extent of its impact, saying that “9/11 was a major wake-up call in the world economy”. Van Reenen highlighted how some companies such as Barclays, for which he previously consulted, had to work to be up and running after the collapse of the Twin Towers in 9/11.

In addition, Van Reenen’s lecture also touched on the importance of the first ninety days of a job after an individual has been employed. “Those first ninety days are crucial, as you have to establish yourself in a company where you are paid less than you are worth,” Van Reenen said. As such, he gave the audience insight into what they could focus on in that time frame. This includes focusing on the small wins, as well as ensuring that you are working at keeping the team together, as the team is an integral part of an organisation. 

Van Reenen concluded his address by speaking about his time as the CEO of the Toyota Free State Cheetahs, including some of the decisions he took to ensure the success of the organisation.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept